Actualités Crescita Therapeutics Inc - CTX | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe PR Newswire VIENNA, June 1, 2023 VIENNA, June...

Crescita Reports First Quarter 2023 Results

Strong Performance in Commercial Skincare Cash Balance of $10.3M Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the...

Crescita Reports Q4 and Fiscal 2022 Results

Record Annual Revenue of $23.5M, Up 40% Over F2021 F2022 Adjusted EBITDA1 of $2.2M, Up 138% Over F2021 Crescita Therapeutics Inc. (TSX: CTX and...

Crescita Reports Third Quarter 2022 Results

Sales Doubled with New Manufacturing Revenue Record of $4.3M Adjusted EBITDA1 of $0.5M, up $1.0M Year-over-Year Cash Balance of...

Crescita Reports Second Quarter 2022 Results

Over 120% sales growth with Record Manufacturing Revenue of $3.9M Adjusted EBITDA1 of $0.6M, up $0.9M Year-over-Year Repayment of $1.0 M of...

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...

Crescita Reports First Quarter 2022 Results

Record Manufacturing Segment Revenue of $3.4M Positive Adjusted EBITDA1 Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or...

Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) today announced that its CEO, Serge Verreault, will be...

Crescita Reports Q4 and Fiscal 2021 Results

– Record Q4, and F2021 Manufacturing Segment Revenue of $5.3M, a 3-fold Increase vs. F2020 – Expansion of Pliaglis® Licenses to 32 New...

Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”...

Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology...

Crescita Reports Third Quarter 2021 Results and Appoints New Board Member

- Pliaglis® Licensed in 15 New Countries - Minority Interest Acquisition of 6 Medical Aesthetic Clinics in Ontario - Deployment of Capital to...

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology company...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Crescita Therapeutics Inc (CTX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CTX Actualités

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

Crescita Reports First Quarter 2023 Results

Crescita Reports Q4 and Fiscal 2022 Results

Crescita Reports Third Quarter 2022 Results

Crescita Reports Second Quarter 2022 Results

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Reports First Quarter 2022 Results

Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference

Crescita Reports Q4 and Fiscal 2021 Results

Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid

Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

Crescita Reports Third Quarter 2021 Results and Appoints New Board Member

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Crescita Therapeutics Inc (CTX) Actualités

Crescita Therapeutics Inc (CTX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CTX Actualités

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Croma-Pharma: Launch of topical anaesthetic Pliaglis® in Europe

Crescita Reports First Quarter 2023 Results

Crescita Reports Q4 and Fiscal 2022 Results

Crescita Reports Third Quarter 2022 Results

Crescita Reports Second Quarter 2022 Results

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

Crescita Reports First Quarter 2022 Results

Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference

Crescita Reports Q4 and Fiscal 2021 Results

Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid

Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

Crescita Reports Third Quarter 2021 Results and Appoints New Board Member

Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres